Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

ORIC Pharmaceuticals, Inc.

ORIC ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$13.63

▼ -1.59%

Market Cap $1.41B · Vol 468.86K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.41B

Small Cap

Div Yield

N/A

EPS Growth

-2.22%

YoY

RSI (14)

63.79

Momentum

Beta

1.17

vs Market

52W High

$14.67

5.59% below

52W Low

$7.23

91.56% above

Volume

468.86K

Avg 537.17K

P/B

2.10

Price-to-book

ROE

-41.27%

Return on equity

Free Float

96.47%

Public shares

Shariah Compliance8 STANDARDS

✗ ORIC Pharmaceuticals, Inc. (ORIC) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ORIC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+6.73%

+0.96%

+26.79%

+26.56%

YTD

+66.63%

+12.83%

+149.63%

-8.52%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-129,468,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-41.27%
ROA · ROIC	-37.91% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.10
P/FCF	N/A
EPS Growth	-2.22%
Outstanding Shares	103.65M

Technical Indicators

50-Day SMA	$12.96
200-Day SMA	$11.13
RSI (14)	63.79
Beta	1.17
52-Week High	$14.67
52-Week Low	$7.23

Volume Today	468.86K
Avg Daily Volume (30D)	537.17K
Relative Volume	0.87x
Volatility (10D)	69.33
Volatility (30D)	55.62
Free Float	96.47%

Analyst Consensus

BUY

Current Price $13.63

Mean Target $21.64

52W Low$7.23 52W High$14.67

Current

Target

$7.23 $14.67

Current Analyst target

+58.79% upside potential · 15 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00BL5SMR2

ISINUS68622P1093

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -6.02% ARGX.BR argenx SE -0.41% ARGX argenx SE -1.61% GMAB.CO Genmab A/S +1.30% GMAB Genmab A/S +1.09%

Company Profile

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.